SLC3A2 and cancer: Specifically, anti-PD-L1 antibodies stimulate CD8+ T cells to release cytokine IFNγ to activate the JAK-STAT1 pathway in cancer cells, thereby reducing the expressions of SLC7A11 and SLC3A2, and ultimately increasing the sensitivity of cancer cells to ferroptosis (Wang et al., 2019).